This post was originally published on this site To enhance care for the growing number of people with Alzheimer’s and other dementia, the U.S. Department of Health and Human Services (HHS) has awarded the University of Oklahoma Health Sciences Center a $3.75 million grant. The grant will establish a partner-reliant program designed to better…
Category: Alzheimer’s
Seizures May Reduce Brain Cell Production, Result in Poor Spatial Discrimination, Mouse Study Suggests
This post was originally published on this site Spontaneous seizures reduce the production of new brain cells, and result in poor spatial discrimination — a common occurrence in people with Alzheimer’s disease, according to a mouse study. The study, “Early Seizure Activity Accelerates Depletion of Hippocampal Neural Stem Cells and Impairs Spatial Discrimination in an…
Low-Carb Diet May Improve Memory in People with Cognitive Problems, Small Study Suggests
This post was originally published on this site A diet low in carbohydrates may have cognitive benefits for older adults with mild cognitive impairment, a small study suggests. “Preliminary Report on the Feasibility and Efficacy of the Modified Atkins Diet for Treatment of Mild Cognitive Impairment and Early Alzheimer’s Disease” was published in the Journal of…
Women Carrying ApoE4 Gene More Susceptible Than Men to Toxic Tau Clumps in Brain, Study Suggests
This post was originally published on this site Women who are carriers of the ApoE4 gene — a major genetic risk factor for the development of a late-onset form of Alzheimer’s disease, are more susceptible than men to accumulating toxic tau protein aggregates in the brain, a study suggests. This finding was shared in a…
Educating Others About Alzheimer’s Disease Can Help to Erase the Stigma
This post was originally published on this site Alzheimer’s disease is a neurodegenerative condition that affects almost 6 million people in the United States. People with the disease experience mental decline, and symptoms include memory loss — but that’s not the only forfeiture. Alzheimer’s is the most common type of dementia. However, despite its prevalence,…
Having Parent or Sibling with Alzheimer’s Linked to Poorer Verbal, Memory Skills in People Taking ‘MindCrowd’ Test
This post was originally published on this site Regardless of sex, people younger than age 65 who have a first-degree relative with Alzheimer’s disease generally showed poorer verbal and memory skills on a web-based test than their peers without this family history, a study’s results show. The study, “Family history of Alzheimer’s disease alters cognition…
Antibiotics Altering Gut Bacteria Reduced Alzheimer’s Symptoms, But Only in Male Mice, Study Shows
This post was originally published on this site Long-term antibiotic treatment, aimed at altering the bacterial population in the gut, was found to reduce the inflammation and amyloid plaque formation that is a hallmark of Alzheimer’s disease — but only in male mice. The same treatment had no effect on female mice, a study found.…
New Genentech Study to Investigate Familial Alzheimer’s Progression and Response to Crenezumab
This post was originally published on this site Genentech, a subsidiary of Roche, has launched a new substudy to learn more about the progression of early-onset familial Alzheimer’s disease, as part of its ongoing Alzheimer’s Prevention Initiative (API) trial evaluating crenezumab for preventing or delaying this genetic form of the disease. This substudy will examine the…
The ‘Longest Day’ Sheds Light on Alzheimer’s Disease
This post was originally published on this site The Alzheimer’s Association has chosen the summer solstice, June 21, to shed light on Alzheimer’s disease and to raise awareness about the mind-altering, life-changing condition through a fundraising event called The Longest Day. The second purpose is to raise funds for research to benefit the 53 million…
1st U.S. Patient Enrolled in Phase 2a Trial Evaluating Vafidemstat for Alzheimer’s
This post was originally published on this site A Phase 2a trial testing Oryzon’s investigational therapy vafidemstat for Alzheimer’s disease has enrolled its first patient in the U.S. The trial (NCT03867253), called ETHERAL-US, is an extension of the European trial (2017-004893-32), currently ongoing at 17 sites in the U.K., France, and Spain. Oryzon is planning…